Senti Bio Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
100
- Stock Symbol
-
SNTI
- Investments
-
2
- Share Price
-
$1.95
- (As of Friday Closing)
Senti Bio General Information
Description
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Contact Information
Website
www.sentibio.comCorporate Office
- 2 Corporate Drive
- First Floor
- South San Francisco, CA 94080
- United States
Corporate Office
- 2 Corporate Drive
- First Floor
- South San Francisco, CA 94080
- United States
Senti Bio Timeline
Senti Bio Stock Performance
As of 18-Jul-2025, Senti Bio’s stock price is $1.95. Its current market cap is $50.9M with 26.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.95 | $2.01 | $1.52 - $16.94 | $50.9M | 26.1M | 337K | -$23.53 |
Senti Bio Financials Summary
As of 31-Mar-2025, Senti Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 97,845 | 40,336 | 27,283 | (19,007) |
| Revenue | 0 | 0 | 1,978 | 3,286 |
| EBITDA | (49,943) | (47,887) | (80,841) | (47,446) |
| Net Income | (54,791) | (52,790) | (71,058) | (58,210) |
| Total Assets | 82,778 | 97,841 | 119,484 | 180,792 |
| Total Debt | 32,445 | 33,641 | 37,666 | 37,091 |
Senti Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Senti Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Senti Bio Comparisons
Industry
Financing
Details
Senti Bio Competitors (48)
One of Senti Bio’s 48 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Agenus | Formerly VC-backed | Lexington, MA |
Senti Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Senti Bio Patents
Senti Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023391848-A1 | Macrophage-specific promoters and uses thereof | Pending | 05-Dec-2022 | ||
| AU-2023375543-A1 | Antigen-binding domains and methods of use thereof | Pending | 09-Nov-2022 | ||
| US-20250222133-A1 | Cell-type specific regulatory elements for photoreceptors | Pending | 30-Sep-2022 | ||
| AU-2023314498-A1 | Inhibitory chimeric receptor architectures | Pending | 26-Jul-2022 | ||
| EP-4562029-A2 | Inhibitory chimeric receptor architectures | Pending | 26-Jul-2022 | C07K14/705 |
Senti Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Senti Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Senti Bio Investments & Acquisitions (2)
Senti Bio’s most recent deal was a Merger/Acquisition with Dynamics Special Purpose for . The deal was made on 08-Jun-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Dynamics Special Purpose | 08-Jun-2022 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Lexent Bio | 01-Nov-2017 | Early Stage VC | Decision/Risk Analysis |
Senti Bio Exits (1)
Senti Bio’s most recent exit was on 01-Nov-2017 from Lexent Bio. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Lexent Bio | 01-Nov-2017 | Completed |
|
Senti Bio FAQs
-
When was Senti Bio founded?
Senti Bio was founded in 2016.
-
Where is Senti Bio headquartered?
Senti Bio is headquartered in South San Francisco, CA.
-
What is the size of Senti Bio?
Senti Bio has 100 total employees.
-
What industry is Senti Bio in?
Senti Bio’s primary industry is Drug Discovery.
-
Is Senti Bio a private or public company?
Senti Bio is a Public company.
-
What is Senti Bio’s stock symbol?
The ticker symbol for Senti Bio is SNTI.
-
What is the current stock price of Senti Bio?
As of 18-Jul-2025 the stock price of Senti Bio is $1.95.
-
What is the current market cap of Senti Bio?
The current market capitalization of Senti Bio is $50.9M.
-
Who are Senti Bio’s competitors?
Kite Pharma, NexImmune, CRISPR Therapeutics, Sorrento Therapeutics, and Agenus are some of the 48 competitors of Senti Bio.
-
What is Senti Bio’s annual earnings per share (EPS)?
Senti Bio’s EPS for 12 months was -$23.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
